title: Gnawing at Metchnikoff's paradigm.
abstract: In this issue of Blood, Rossi et al provide convincing evidence that extends and generalizes the importance of trogocytosis, a process in which effector cells use Fcg receptors to remove Immunoglobulin G (IgG)-chelated antigens from donor cells. Their work suggests that the process may be beneficial in the context of epratuzumab treatment of autoimmune diseases.
authors.affiliation: UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE.
authors.forename: Ronald P
authors.initials: RP
authors.lastname: Taylor
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000187:drug effects*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D010587:Phagocytosis / Q000187:drug effects*; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C497867:CD22 protein, human; D051918:Sialic Acid Binding Ig-like Lectin 2; C448700:epratuzumab